BCLS Acquisition Corp. is a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities.
While the Company may pursue an acquisition opportunity in any business, industry, sector or geographical location, it intends to pursue investments, primarily based in North America and Europe and selectively in other geographies, including Asia and emerging markets, in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies. The Company is sponsored by an affiliate of Bain Capital Life Sciences, a leading life sciences investment manager.
Company profile
Ticker
BLSA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
BLSA stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
7 Nov 22
25-NSE
Exchange delisting
26 Oct 22
8-K
BCLS Acquisition Corp. will redeem its Public Shares and will not consummate an initial business combination
21 Oct 22
UPLOAD
Letter from SEC
15 Sep 22
CORRESP
Correspondence with SEC
6 Sep 22
UPLOAD
Letter from SEC
18 Aug 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Mar 22
10-K/A
2020 FY
Annual report (amended)
30 Dec 21
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
ACUTA CAPITAL PARTNERS, LLC
14 Feb 23
SC 13G/A
FEDERATED HERMES, INC.
7 Dec 22
SC 13G
ACUTA CAPITAL PARTNERS, LLC
15 Feb 22
SC 13G/A
PERCEPTIVE ADVISORS LLC
15 Feb 22
SC 13G/A
FEDERATED HERMES, INC.
14 Feb 22
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 22
SC 13G
RA CAPITAL MANAGEMENT, L.P.
16 Feb 21
SC 13G/A
PERCEPTIVE ADVISORS LLC
16 Feb 21
SC 13G
FEDERATED HERMES, INC.
12 Feb 21
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 639.69 k | 639.69 k | 639.69 k | 639.69 k | 639.69 k | |
Cash burn (monthly) | (no burn) | 11.93 k | 84.88 k | 78.13 k | (no burn) | |
Cash used (since last report) | n/a | 261.13 k | 1.86 mm | 1.71 mm | n/a | |
Cash remaining | n/a | 378.56 k | -1.22 mm | -1.07 mm | n/a | |
Runway (months of cash) | n/a | 31.7 | -14.4 | -13.7 | n/a |
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 3 |
Closed positions | 11 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 150.23 mm |
Total shares | 14.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 1.25 mm | $12.53 mm |
Adage Capital Partners GP, L.L.C. | 1.24 mm | $12.40 mm |
Glazer Capital | 1.20 mm | $12.06 mm |
FHI Federated Hermes Inc - Ordinary Shares | 1.00 mm | $10.02 mm |
Acuta Capital Partners | 843.12 k | $8.45 mm |
Citadel Advisors | 689.02 k | $6.90 mm |
T. Rowe Price | 677.72 k | $6.79 mm |
Sculptor Capital | 634.72 k | $6.36 mm |
RTW Investments | 612.50 k | $6.14 mm |
D. E. Shaw & Co. | 530.79 k | $5.32 mm |